Document:

Joint Research Agreement

 Exhibit 10.10 
 I. Project Name: 
 Joint Research on Anti-tumor Drug AL6802 
 II. Content, Scope, Mode and Requirement: 
 Content and cooperation mode: Party A shall provide
human resources and financial support while Party B shall provide technologies, including those technologies on which Party B has already filed an application for U.S. patent and will file an application for PCT patent before January 17, 2007.
Parties hereto shall work together to complete the research and development of anti-tumor drug AL6802 (a chemical compound that covered by the pending U.S. patent and the future PCT patent application mentioned above) in China (and other countries
and regions outside China), and finally have AL6802 pharmaceutical registration and invention patent granted in China mainland and carry out relevant commercial development in China and other countries and regions outside China. 
 1. Party A’s Obligations: 
  

	 	1)	Party A shall be responsible for the preparation of samples and the preclinical and clinical research on the pharmacodynamics, pharmacokinetics, toxicity, synthesis process,
structure identification, formulation, quality standard, stability of the samples according to the information provided by Party B and under the guidance of Party B, and shall provide one copy of the all reports to Party B. 

 

	 	2)	Party A shall pay patent application right transfer fee in installments to Party B in accordance with this Agreement. Party A shall provide convenience on food and accommodation as
well as two technicians, for the sample’s amplification in early phase, with at least three-year chemical synthesis experience to Party B’s researchers when they work in Party A’s site. 

  

	 	3)	If Party A does not pay corresponding fees in accordance with time schedule to Party B and therefore cause the termination of the cooperation, or no actual development in any
consecutive 24 months during the developing phase, it shall be deemed as that Party A returns relevant patent application right and patent right granted in future to Party B. 

	 	4)	In case this project obtains grants from Ministry of Science and Technology or relevant departments at provincial or municipal level, and relevant administrative policies permits,
Party A shall pay 10% of the grants to Party B to fund the research and development under this project, such as the research and development on the formulation and crystallization of AL6802. Parties hereto agree that, for the achievement generated
from the research and development subsequent to this project and relevant patent application, any and all rights and interests therewith within China shall exclusively belong to Party A while any and all rights and interests therewith outside China
shall be shared by parties hereto equally. 

  

	 	5)	 Party A shall, in accordance with State Food and Drug Administration’s requirements about the pre-clinical pharmacodynamics study of anti-tumor drug, use the
AL6802 sample with a concentration no less than 98.5%, with the erlotinib hydrochloride as the positive control, to evaluate the pharmacodynamics and toxicology of AL6802 towards non-small cell lung cancer cell line A549 and H157 and human
epidermoid carcinoma cell line A431 transplanted nude mice respectively. If the experiment results show that the efficacy of AL6802 is significantly lower than positive control erlotinib hydrochloride (P <0.05) statistically; or the toxicity of
AL6802 is significantly higher than positive control erlotinib hydrochloride (P <0.05) statistically, Party A shall be entitled to terminate the research and development of the compound and shall be entitled not to pay the third installment of
the pre-clinical costs. If Party A chooses another compound under the US patent application US60/759,601 for research, Party B shall be responsible for the provision of synthesis technologies of the selected compound upon Party A’s request, and
Party A shall undertake the synthesis cost of the selected compound and be responsible for the evaluation of the pharmacodynamics and toxicology of the selected compound. If Party A identifies a compound for the development, parties hereto shall
continue the cooperation in accordance with relevant terms and conditions of this Agreement, and the term “AL6802” indicated in this Agreement shall be automatically replaced by the name of the compound identified otherwise. Under such
conditions, Party A shall 

	 	 
be entitled not to pay the first installment of RMB 2,000,000 once more and halve the second and third installment (ie, reduced to RMB 500,000 respectively).
Other provisions shall remain unchanged, and parties hereto shall continue the cooperation in accordance with relevant provisions of this Agreement. 

  

	 	6)	This project shall be terminated if AL6802 involved in the project infringing other natural person or company’s patent. The report issued by Guozhi Enterprise Patent
Warning and Advisory Services Center under State Intellectual Property Office of People’s Republic of China, or the effective judgment made by the People’s court shall be regarded as the judgment standards about the patent infringement.
Party A shall be entitled to require Party B to return all fees paid within 30 days as of the date the report is issued or the judgment goes into effect. 

  

	 	7)	Party A shall promise not to develop any compound with the chemical structure similar to AL6802 during the cooperation term or 5 years after the termination of the cooperation.

  

	 	8)	Party A shall be entitled to transfer or license relevant technologies, patent application right or patent right possibly granted in future to its affiliated company within the same
companies group. Such transfer or license shall be deemed as the exercise of relevant rights under this Agreement by Party A. 

 2. Party B’s Obligations 
  

	 	1)	Party B shall provide patent application documents on AL6802, compound structural formula, detail analysis data of structural confirmation, synthesis procedure data and etc. Party B
shall direct Party A to prepare three consecutive batches of qualified AL6802 samples with stable physical and chemical properties at Party A’s site (the concentration of each batch shall not be less than 98.5% and the weight of each batch
shall not be less than 25g). Whereas Party B promises that its synthesis technology about Al6802 are mature and the compound is stable, if Party A fails, despite that Party A cooperates with Party B actively, to produce AL6802 samples with the
concentration and weight described above within four months as from the date this Agreement is signed and goes into effect, Party A shall be entitled to request Party B to resolve the technical problem within one month as from the date
abovementioned four-month expires. Otherwise, Party A shall be entitled to terminate this Agreement and require Party B to return all fees paid. 

	 	2)	Party B shall transfer to Party A AL6802 samples, relevant technologies and the patent application right within China under the PCT patent application based on United States patent
application US 60/759,601, and shall be responsible for the subsequent patent application in China till relevant patent right is granted. After the patent right is granted in China, Party A shall be responsible for the annual fees and relevant
maintenance about the patent, and Party B shall assist Party A to maintain the patent till its expiration. 

  

	 	3)	Party B shall keep a close cooperation with Party A to seek global development partner(s) outside China. Party B agrees that each party shall enjoy 50% of all the rights and
interests of AL6802 outside China, including but not limited to the patent under the US 60/759,601 patent application and the patent application rights transfer fees, royalty, technology transfer fees, license fees regarding the PCT patent based on
the patent under the US 60/759,601 patent application. The license, transfer and other cooperation about the rights and interests regarding compound AL6802 outside China shall be subject to the written agreement between parties hereto.

  

	 	4)	Whereas the promise of Party B that the compound AL6802 has the possibility to obtain invention patent right(s) in China is one of the prerequisites of the cooperation under this
Agreement, if Guozhi Enterprise Patent Warning and Advisory Services Center under the State Intellectual Property Office of PRC issues a report which indicates that the compound AL6802 is unlikely to be granted patent in China, Party A shall
be entitled to abandon the further development. The risks of early cooperation shall be jointly undertaken by parties hereto, and Party B shall therefore return 50% of all costs Party A has paid within 30 days as from the date said report is issued.

  

	 	5)	 Party B shall be responsible for the patent application of US 60/759,601 and the subsequent global PCT patent application based on the US 60/759,601 application. It
is agreed that Party A shall exclusively enjoy all patent rights under the PCT 

	 	 
patent based on United States patent application US 60/759,601 (including the right to transfer or license such patent rights to Party A’s Affiliates at
its sole discretion) and undertake any and all patent application fees, patent maintenance fees in China, while the patent application fees and patent maintenance fees outside China shall be equally shared by both parties hereto, the patent right
shall be equally shared by both parties hereto, and any transfer or license concerning such patent shall be subject to written consent of parties hereto. Parties hereto agree that the right to utilize the chemical compounds and fragments without
anti-tumor activities involved in such patent for other purpose shall exclusively belong to Party B. 

  

	 	6)	During the term of this Agreement, if Party B transfers or license the AL6802 and relevant technologies to a third party without Party A’s prior consent, Party A shall be
entitled to request a compensation of no less than three times the total contract price of this Agreement (RMB 30,000,000) from Party B. If Party A transfers or license the AL6802 and relevant technologies to a third party without Party B’s
prior consent, Party B shall be entitled to request a compensation of no less than three times the total cooperation fund of this Agreement (RMB 30,000,000) from Party A except that Party A transfers or licenses said technologies to Party A’s
Affiliates. 

  

	 	7)	During the term of this Agreement, if a third party’s cooperation may advance the project progress, with the consensus of parties hereto, Party A and Party B may jointly
transfer relevant technologies to said third party. Party A shall be entitled to recover its investment from the royalty paid by said third party. 

  

	 	8)	Party B shall confirm that technologies transferred under this Agreement may be used to produce qualified AL6802 compound under this Agreement and the compound itself and the entire
production process including raw materials, workmanship, intermediate compounds, and methods do not infringe any rights of other person or entities. Otherwise, Party A shall be entitled to terminate this Agreement and request Party B to refund all
the payment. 

  

 III. Schedule, Progress, Date, Place and Implementation Mode: 
  

	 	

			
	 Dec. 2006 ~ Mar. 2007
  
 Mar. 2007 ~ May 2007
  
 Jun. 2007 ~ Jun. 2008
  
 Jun. 2008 ~ Mar. 2009

 
 Mar. 2009 ~ Dec. 2011
	  	 Technical handover of the synthesis procedure
  
 Further pharmacodynamics verification
  
 Preclinical research
  
 Apply for clinical
research
  
 Clinical research, obtain certificate of manufacture

 Above schedule shall be rearranged correspondingly in case the actual situation about the research
and application or relevant laws or regulations change, and parties hereto shall actively cooperate with each other to complete the project as soon as possible. 
 IV. Technical Cooperation Fund, Royalties on Sales and Payment Mode 
 The total cooperation fund for the research and
development under this project shall be RMB thirty millions (RMB 30,000,000), which shall be paid by Party A to Party B in six installments as patent licensing fees. Said total cooperation fund shall cover any and all fees and expenses involving
this Agreement. Besides the cooperation fund, Party A shall be entitled not to make any additional payments. But the oversea patent application fees and subsequent maintenance fees and the research and development fee for oversea institutes, which
shall be paid by Party A in accordance with relevant provisions, is not inclusive. 
  

	 	1.	RMB 2,000,000 (RMB two millions) shall be paid within two weeks after the effective date of this agreement; 

  

	 	2.	RMB1,000,000 (RMB one million) shall be paid within two weeks as of the date parties hereto confirm the qualified completion of the technical handover of the synthesis procedure;

	 	3.	RMB1,000,000 (RMB one million) RMB shall be paid within two weeks before the official launch of the preclinical research if the further pharmacodynamics and toxicity verification
shows that AL6802’s pharmacodynamics equals to or is better than positive control erlotinib hydrochloride (P>0.05) statistically, and AL6802’s toxicity equals to or is better than positive control erlotinib hydrochloride (P>0.05)
statistically; 

  

	 	4.	RMB 6,000,000 (RMB six millions) shall be paid within four weeks after obtaining the clinical trial approval; 

  

	 	5.	RMB 5,000,000 (RMB five millions) shall be paid within two weeks before launching phase III clinical research if Party A is satisfied with the phase II clinical trial results;

  

	 	6.	RMB 15,000,000 (RMB fifteen millions) shall be paid within eight weeks after obtaining the new drug certificate; 

  

	 	7.	3.5% of net sales shall be paid to Party B as royalties on sales after the anti-tumor drug AL6802 is brought into market. “Net sales” shall mean the gross sales deducting
packing fees, transportation fees, taxes, advertisement fees, commercial discount. The period for the royalties shall be the patent protection period of AL6802 in China. 

 V. Confidentiality and Subsequent Improvement 
  

	 	1.	Parties hereto shall keep any and all nonpublic technical information and research confidential, and shall not make any disclosure to the public. In case either party violates the
confidentiality requirements, the other party shall be entitled to claim for any and all compensation arising from the unauthorized disclosure to such default party. Some research achievements may be disclosed to potential global cooperation
partners after relevant nondisclosure agreement is signed. 

  

	 	2.	Any and all patentable subsequent improvements to AL6802 shall be patented by parties hereto jointly. The interests of such technical achievements and patents shall exclusively
belong to Party A in China, shall be equally shared by parties hereto outside China. 

 VI. Risks 
 Research risks shall be equally undertaken by parties hereto. 
 VII. Technical Achievements(Patents) and Properties Purchased with Technical
Cooperation Fund 
  

	 	1.	Technical Achievements shall belong to parties hereto. The new drug certificate shall exclusively belong to Party A, but Party B shall have the right of attribution.

  

	 	2.	Party B shall transfer the PCT patent based on US patent application US 60/759,601 and relevant priority, which designated state is China, to Party A, while PCT patents based on US
patent application US 60/759,601 and relevant priority, which designated state is other countries, shall be equally shared by Party A and Party B. Parties shall closely work on patent license and research and development regarding AL6802 outside
China. 

  

	 	3.	Either party shall obtain the other party’s prior consent if said party wants to publish research articles regarding the project. 

 VIII. Disputes Settlement 
 Any and all disputes shall
be settled through negotiation. In case of failure to be settled through negotiation, such disputes shall be submitted to People’s Court at the location of Party A for judgment in accordance with applicable laws of People’s Republic of
China. 

 IX. Miscellaneous 
 This Agreement is executed in four counterparts, and parties hereto each shall keep two counterparts. In case of any contradiction arising between the Chinese version and English Version, the Chinese version shall
prevail. 

			
		  	Jiangsu Simcere Pharmaceutical R&D Co., Ltd
		  	Address: No.12 Hua Yuan Road, Nanjing City, Jiangsu Province
		  	Telephone No.: 0086-25-85477000
	Party A	  	Bank: Changfu Street Branch, Nanjing, China Merchants Bank
		  	Account No.: 07872125903581810106
		  	Legal Representative:
		  	                                        
     Date

		
		  	Advenchen Laboratories LLC
		  	Address: 9135 Reseda Blvd, STE 238, Northridge CA 91324, USA
		  	Telephone No.: 001-626-482-9676
	Party B	  	Bank:
		  	Account No.:
		  	Legal Representative:
		  	                                        
     DateAmended and Restated Employment Agreement dated as of July 31, 1998

 Exhibit 10.1 
 AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT 
 This Amendment to the Amended and Restated
Employment Agreement (“Employment Agreement”), dated as of July 31, 1998 and amended as of September 30, 1999 between Ventas, Inc., a Delaware corporation (the “Company”), and T. Richard Riney (the
“Executive”) is made as of March 19, 2007. 
 WITNESSETH: 
 WHEREAS, the Executive and the Company entered into the Employment Agreement; 
 WHEREAS, the Executive Compensation Committee of the Board of Directors of the Company has determined that it is in the best interests of the
Company to enter into this Amendment to the Employment Agreement. 
 NOW, THEREFORE, the Company and Executive agree as follows:

 1. Section 7(b) of the Employment Agreement is amended and restated in its entirety as follows: 
 (b) Good Reason; Other than for Cause. If, during the Term, the Company shall terminate Executive’s employment other than for Cause (but not
for Disability), or the Executive shall terminate his employment for Good Reason: 
 (1) Within fourteen (14) days of Executive’s
Date of Termination, the Company shall pay to Executive (i) the prorated portion of the Target Bonus for Executive for the year in which the Date of Termination occurs, plus (ii) an amount equal to the Executive’s Base Salary and
Target Bonus as of the Date of Termination. For purposes of this Agreement: “Target Bonus” shall mean the full amount of bonuses and/or performance compensation (other than Base Salary and awards under the Company’s 1997 Incentive
Compensation Plan) that would be payable to the Executive, assuming all performance criteria on which such bonus and/or performance compensation are based were deemed to be satisfied, in respect of services for the calendar year in which the date in
question occurs. 
 Notwithstanding the foregoing, in no event shall the payment made pursuant to this Section 7(b)(1) be in excess of
the Maximum Amount. The term Maximum Amount, for purposes of this Agreement, shall mean $3,000,000, provided, however, that for any termination that occurs in calendar years subsequent to 2007, the Maximum Amount will be adjusted to reflect
increases, if any, in the Consumer Price Index that have occurred in the period between December 31, 2006 and the end of the calendar year immediately preceding the date of termination. As an example, if the termination occurs in 2008, the
Maximum Amount shall be adjusted for increases in the Consumer Price Index that occur between December 31, 2006-December 31, 2007 and if the termination occurs in 2009, the Maximum Amount shall be adjusted for increases in the Consumer
Price Index that occur between December 31, 2006-December 31, 2008. For purposes of this Agreement, Consumer Price Index means the CPI for All Urban Consumers (All Items; Base Year 1982 ), compiled and published by the Bureau of Labor
Statistics of the United States Department of Labor. 
  

 -1- 

 (2) For a period of one year following the Date of Termination, the Executive shall be treated as if he
or she had continued to be an Executive for all purposes under the Company’s Health Insurance Plan and Dental Insurance Plan; or if the Company has not yet established its own Health Insurance Plan and/or Dental Plan or the Executive is
prohibited from participating in such plan, the Company shall, at its sole cost and expense, provide health and dental insurance coverage for Executive which is equivalent to the coverage provided to Executive as of the Date of Termination.
Following this continuation period, the Executive shall be entitled to receive continuation coverage under Part 6 of Title I or ERISA (“COBRA Benefits”) treating the end of this period as a termination of the Executive’s employment if
allowed by law. 
 (3) For a period of one year following the Date of Termination, Company shall maintain in force, at its expense, the
Executive’s life insurance being provided by the Company as of the Date of Termination. 
 (4) For a period of one year following the
Executive’s Date of Termination, the Company shall provide short-term and long-term disability insurance benefits to Executive equivalent to the coverage that the Executive would have had he remained employed under the disability insurance
plans applicable to Executive on the Date of Termination. Should Executive become disabled during such period, Executive shall be entitled to receive such benefits, and for such duration, as the applicable plan provides. 
 (5) To the extent not already vested pursuant to the terms of such plan, the Executive’s interests under the Vencor, Inc. Retirement Savings Plan
and any Retirement Savings Plan of the Company shall be automatically fully (i.e., 100%) vested, without regard to otherwise applicable percentages for the vesting of employer matching contributions based upon the Executive’s years of service
with the Company. 
 (6) The Company shall adopt such amendments to its Executive benefit plans, if any, as are necessary to effectuate the
provisions of this Agreement. 
 (7) Executive shall be credited with an additional one year of vesting for purposes of all restricted stock
awards and Executive will have an additional one year in which to exercise all outstanding stock option awards. 
 (8) The Company shall pay
Executive within 30 days of the date of termination of employment (but not earlier than the date on which the Release becomes irrevocable) a lump sum payment equal to the amount of awards under the Company’s Performance Cash Plan
(“PCP”) that are based on actual performance for completed fiscal years but have not yet been paid. As an example, assume that Executive, following the 2006 fiscal year, was awarded a PCP award of $100 that would, assuming continuous
employment, have been paid out following the end of the 2008 fiscal year (the “Outstanding PCP Award”). Upon a termination subject to this Section 7(b) that occurs prior to the payment of such Outstanding PCP Award, the Company would
be obligated, pursuant to this Section 7(b)(8), to pay Executive $100 in respect of such Outstanding PCP Award. 
  

 -2- 

 2. A new Section 19 will be added to the Employment Agreement, as follows: 
 19. COMPLIANCE WITH SECTION 409A OF THE INTERNAL REVENUE CODE. All payments pursuant to this Agreement shall be subject to the
provisions of this Section 19. If Executive is a “Specified Employee” of the Company for purposes of Internal Revenue Code Section 409A (“Code Section 409A”) at the time of a payment event set forth in this Agreement, then no
severance or other payments pursuant to this Agreement shall be made to Executive by the Company until the amount of time has passed that is necessary to avoid incurring excise taxes under Code Section 409A. Should this Section 19 result in a delay
of payments to Executive, on the first day any such payments may be made without incurring a penalty pursuant to Code Section 409A (the “409A Payment Date”), the Company shall begin to make such payments as provided for in this Agreement,
provided that any amounts that would have been payable earlier but for the application of this Section 19, shall be paid in lump-sum on the 409A Payment Date along with accrued interest at the rate of interest published in the Wall Street Journal as
the “prime rate” (or equivalent) on the date that payments to Executive should have been made under this Agreement. For purposes of this provision, the term Specified Employee shall have the meaning set forth in Section 409A(2)(B)(i) of
the Internal Revenue Code of 1986, as amended or any successor provision and the treasury regulations and rulings issued thereunder. If any compensation or benefits provided by this Agreement may result in the application of Code Section 409A, the
Company shall, in consultation with the Executive, modify the Agreement in the least restrictive manner necessary in order to exclude such compensation from the definition of “deferred compensation” within the meaning of such Code Section
409A or in order to comply with the provisions of Code Section 409A of the Code and without any diminution in the value of the payments or benefits to the Executive. 
 3. In all other respects, the Employment Agreement shall continue in full force and effect. 
 * * * * * * * *
* 
  

 -3- 

			
	VENTAS, INC.
		
	By:	 	 /s/ Debra A. Cafaro

		 	Debra A. Cafaro,
		 	President and Chief Executive Officer
	
	EXECUTIVE
		
	By:	 	 /s/ T. Richard Riney

		 	T. Richard Riney

  

 -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]